Solara Active Pharma Sciences Limited — Investor Meet, 28-10-2024: Analysts/Institutional Investor Meet/Con. Call Updates

Solara Active Pharma Sciences Limited reported a strong Q2 performance with gross margins reaching 50.5%, a 620 basis point improvement year-on-year. EBITDA for the quarter grew 46% sequentially to INR 61 crores. Notably, 76% of revenues came from regulated markets, indicating solid focus on profitability. The company is optimistic about its future, planning for growth in its Vizag facility by FY ’26. Positive progress has been noted with three significant quality approvals received recently.